Tina deVries
2017
In 2017, Tina deVries earned a total compensation of $585.7K as EVP, Research & Development at RVL Pharmaceuticals plc.
Compensation breakdown
| Non-Equity Incentive Plan | $191,738 |
|---|---|
| Salary | $383,178 |
| Other | $10,800 |
| Total | $585,716 |
deVries received $383.2K in salary, accounting for 65% of the total pay in 2017.
deVries also received $191.7K in non-equity incentive plan and $10.8K in other compensation.
Rankings
In 2017, Tina deVries' compensation ranked 11,279th out of 14,666 executives tracked by ExecPay. In other words, deVries earned more than 23.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,279 out of 14,666 | 23rd |
Division Manufacturing | 4,424 out of 5,772 | 23rd |
Major group Chemicals And Allied Products | 1,608 out of 2,075 | 23rd |
Industry group Drugs | 1,325 out of 1,731 | 24th |
Industry Pharmaceutical Preparations | 1,036 out of 1,333 | 22nd |
Source: SEC filing on April 26, 2019.
deVries' colleagues
We found one more compensation record of an executive who worked with Tina deVries at RVL Pharmaceuticals plc in 2017.
2017
Brian Markison
RVL Pharmaceuticals plc
Chief Executive Officer
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019